Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: the oversold’s ground moved upward

December 16, 2019 5:35pm

The downside trippers (13) were percentage (%) lean and volume weak while the elevated upside’s (25) percentage (%) and volume increased

Shaking the December tree, 5 negative and 6 positive closes … so far

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

There is no breadline for share pricing and fact based intelligence!

The Dow closed UP +100.51 points (+0.36%), the S&P closed UP +22.65 points (+0.71%) and the NASDAQ closed UP +79.35 points (+0.91%)

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday the IBB closed up +1.04% while the XBI closed up +1.18%
Friday the IBB closed up +0.34% while the XBI closed up +0.54%

The advance/decline line scenario of 45 covered companies:

Monday the close was positive with an A/D line of 13/25, 1 flat, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 2 acquired;
Friday the close was negative with an A/D line of 16/24, 1 flat, 1 reversed merged (HSGX), 1 dropped (BTX) and 2 acquired;

Henry’omics:

Sector equities posted solid gains last week in anticipation of the macro moves based on the “potential” tariff/trade agreement with China.

Indexes hit record highs on Monday and were on pace for their fourth straight gain as a so-called phase one trade deal between China and the U.S. clears the path higher for the year to end on a positive note.

Sentiment was also lifted by strong economic data out of China. Chinese industrial production rose 6.2% in November on a year-over-year basis, topping expectations. Retail sales in China also jumped 8% last month <CNBC>.

From this morning’s “Data Docket” post, the National Association of Home Builders/Wells Fargo Housing Market Index rose in December to its highest level in 20 years. Meanwhile, data from IHS Markit showed U.S. business activity hit a five-month high in December.

Love the upside moves on market’s momentum; however, the “machines” – electronic trading and algorithms will be stalking the upside moves – skim and slim!

Decliners:

Sage therapeutics (SAGE -$2.87);
uniQure (QURE -$0.60 after Friday’s +$5.09 and Thursday’s +$3.45);
AxoGen (AXGN -$0.45)
Cellectis SA (CLLS -$0.31);
Sangamo Therapeutics (SGMO -$0.14);

Incliners:

ReNeuron (RENE. L +$15.00);
BioMarin Pharmaceuticals (BMRN +$3.33 after Friday’s -$0.73 and Thursday’s +$2.13);
Spark therapeutics (ONCE +$2.82);
Alnylam Pharmaceuticals (ALNY +$2.38 after Friday’s -$2.87, Thursday’s +$1.82 and Wednesday’s -$3.05);
Ionis Pharmaceuticals (IONS +$2.22 after Friday’s +$0.83);

The percentage (%) indicators:

Monday’s range of the 25 upside was +0.57% (MDXG) to +13.66% (BLCM) while the 13 downside ranged from -0.08% (BOLD) to -3.94% (SAGE);
Friday’s range of the 16 upside was +0.012% (RARE) to +7.39% () while the 24 downside ranged from -0.01% (GBT) to -6.66% (BLCM);

Upside volume stats: to compare

Monday: 14 out of the 25 upside had higher than the 3 month average volume;
Friday: 7 out of the 16 upside had higher than the 3 month average volume;

Downside volume stats:

Monday: 9 out of the 13 downside had higher than the 3 month average volume;
Friday: 7 out of the 24 downside had higher than the 3 month average volume;

1 flat – BSTG with Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

December’s sessions:

Monday closed POSITIVE with 13 decliners, 25 advancers, 1 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Friday closed NEGATIVE with 24 decliners, 16 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 14 decliners, 27 advancers, 0 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 13 decliners, 27 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 22 advancers, 2 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 9 decliners, 29 advancers, 3 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 13 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 12 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 26 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

9 hours 7 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.